[Subretinal fluid associated with MEK and BRAF inhibitors]

J Fr Ophtalmol. 2022 Nov;45(9):1091-1092. doi: 10.1016/j.jfo.2022.05.007. Epub 2022 Jul 28.

[Article in French]

Authors

R Attia¹, A Comet², N Stolowy², R Fitoussi², T Michel², D Denis², T David²

Affiliations

¹ Service d'ophtalmologie, CHU de Timone, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: rubat@hotmail.fr.
² Service d'ophtalmologie, CHU de Timone, 264, rue Saint-Pierre, 13385 Marseille, France.

PMID: 35908992
DOI: 10.1016/j.jfo.2022.05.007

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Melanoma* / drug therapy
Mitogen-Activated Protein Kinase Kinases / therapeutic use
Mutation
Protein Kinase Inhibitors / adverse effects
Proto-Oncogene Proteins B-raf* / genetics
Proto-Oncogene Proteins B-raf* / therapeutic use
Subretinal Fluid

Substances

Proto-Oncogene Proteins B-raf
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases
BRAF protein, human